Aurora Cannabis Inc. ACB PHARMA
Company Overview
Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products. It also provides harvested cannabis, trim, cannabis oils, capsules, edibles, vaporizers, dried and fresh cannabis, cannabis plants, cannabis seeds, edible cannabis, cannabis extracts, flowers, vapes / inhalable extracts, edibles / pastilles, concentrates, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes Aurora, Being, CanniMed, CraftPlant, Daily Special, Drift, Greybeard, IndiMed, MedReleaf, Pedanios, San Raf, Tasty's, Whistler, and WMMC. The company also engages in pharmacy activities. Aurora Cannabis Inc. was founded in 2013 and is headquartered in Edmonton, Canada.
Why Investors Should Care
Revenue has grown at a 13.1% CAGR over the past five years.
Recent Developments
- Mar 2026 Revenue of $320.59M (+11.0% YoY); net profit $-135.96M.
- Trailing 12 Months Year-on-year growth — revenue -8.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.14% |
| 1 Year: | -8.80% |
Stock Price Performance
| 1 Year: | -30.02% |
| 6 Months: | +10.57% |
| 3 Months: | +13.49% |
| 1 Month: | +29.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.1% over 5 years.
CONS
- Trading 37.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACB Aurora Cannabis Inc. PHARMA | 3.87 | -5.86 | $245.01M | 0.00% | -8.74% | -9.40% | 13.14% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 90.54M | 98.02M | 90.37M | 94.19M | 38.01M |
| Cost of Revenue | - | 68.64M | 70.07M | 58.08M | 47.57M | 8.22M |
| Gross Profit | - | 21.90M | 27.95M | 32.29M | 46.62M | 29.79M |
| Operating Expenses | - | 50.15M | 48.17M | 50.56M | 44.44M | 39.82M |
| Operating Income | - | -28.25M | -20.22M | -18.27M | 2.18M | -10.03M |
| EBITDA | - | -11.43M | -11.43M | -38.52M | 6.92M | 3.70M |
| Interest Expense | - | 2.61M | 1.77M | 2.22M | 2.11M | -4.29M |
| Pretax Income | - | -19.99M | -19.38M | -46.98M | -1.58M | 11.41M |
| Tax Provision | - | 1.99M | -3.00K | 6.19M | 164.00K | -4.26M |
| Net Income | - | -24.56M | -15.21M | -51.47M | 1.82M | -71.10M |
| Diluted EPS | 0.51 | - | -0.27 | -0.91 | 0.03 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 221.34M | 269.64M | 288.91M | 320.59M |
| Cost of Revenue | 200.11M | 137.91M | 107.96M | 183.94M |
| Gross Profit | 21.23M | 131.73M | 180.95M | 136.65M |
| Operating Expenses | 240.60M | 162.78M | 170.52M | 183.31M |
| Operating Income | -219.38M | -31.05M | 10.43M | -46.66M |
| EBITDA | -1.55B | -11.06M | 46.41M | -40.52M |
| Interest Expense | 71.81M | 13.80M | 2.52M | 1.81M |
| Pretax Income | -1.72B | -57.64M | 31.30M | -56.52M |
| Tax Provision | -2.14M | -554.00K | 4.25M | 2.10M |
| Net Income | -1.72B | -69.33M | 1.59M | -135.96M |
| Diluted EPS | -79.90 | -1.52 | 0.04 | -2.14 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 1.08B | 838.67M | 852.67M | 601.09M |
| Current Assets | 745.12M | 426.61M | 478.33M | 397.45M |
| Cash & Equivalents | 437.81M | 136.09M | 137.92M | 64.69M |
| Inventory | 139.93M | 186.38M | 239.09M | 175.07M |
| Receivables | 28.66M | 40.54M | 35.02M | 41.97M |
| Total Liabilities | 422.00M | 236.80M | 244.07M | 89.25M |
| Current Liabilities | 130.86M | 124.62M | 110.86M | 66.93M |
| Long Term Debt | 199.65M | 4.90M | 40.19M | - |
| Total Debt | 269.49M | 104.79M | 104.58M | 23.86M |
| Total Equity | 661.84M | 559.77M | 567.17M | 511.83M |
| Shares Outstanding | 29.78M | 54.55M | 56.23M | 58.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | -110.27M | -68.51M | 16.01M | -13.51M |
| Investing Cash Flow | -36.17M | -3.36M | -14.33M | -72.61M |
| Financing Cash Flow | 147.78M | -47.92M | -116.00K | 9.76M |
| Capital Expenditure | -32.21M | -16.83M | -15.05M | -22.55M |
| Free Cash Flow | -142.48M | -85.34M | 952.00K | -36.06M |
| Net Change in Cash | 1.34M | -119.79M | 1.56M | -76.36M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 9.6% | 48.9% | 62.6% | 42.6% |
| Operating Margin % | -99.1% | -11.5% | 3.6% | -14.6% |
| Net Margin % | -776.0% | -25.7% | 0.6% | -42.4% |
| ROE % | -259.5% | -12.4% | 0.3% | -26.6% |
| ROCE % | -23.0% | -4.3% | 1.4% | -8.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Goldman Sachs Group Inc | 2.08% | 1.35M | $5.23M |
| 2 | Tidal Investments LLC | 1.95% | 1.26M | $4.89M |
| 3 | Renaissance Technologies, LLC | 1.21% | 784.96K | $3.04M |
| 4 | National Bank of Canada/FI/ | 0.37% | 241.06K | $932.88K |
| 5 | Morgan Stanley | 0.37% | 240.70K | $931.50K |
| 6 | UBS Group AG | 0.27% | 177.56K | $687.16K |
| 7 | AdvisorShares Investments, LLC | 0.26% | 171.11K | $662.20K |
| 8 | Sculptor Capital LP | 0.16% | 103.70K | $401.32K |
| 9 | Citigroup Inc. | 0.15% | 99.20K | $383.90K |
| 10 | TD Asset Management, Inc | 0.15% | 94.65K | $366.30K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACB
Curaleaf Issues Fact Sheet to Address What It Believes Are Misleading Statements From Aurora
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer and medical cannabis products, today released a fact sheet addressing a number of inaccurate and misleading state…
Aurora Cannabis Urges Shareholders to Reject Curaleaf's Takeover Bid
Aurora Cannabis (ACB.TO) urged shareholders to reject Curaleaf Holdings (CURA.TO)'s unsolicited take
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Aurora Cannabis Urged Shareholders to Reject Curaleaf’s Hostile Takeover Bid Tilray Expanded Global Cannabis Production as International Medical Demand Continues to Grow Key Takeaways; Psychedelic Sector Jupit…
Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?
Aurora's turnaround could make Curaleaf's offer look too low.
Curaleaf And Aurora Are Now Sniping At Each Other
Like Logan Roy on HBO, Aurora CEO Miguel Martin is fending off a bear hug. We’ll see if a deal gets done.
Curaleaf Rejects Aurora Defense, Reiterates $4 Premium Offer
In a statement on Monday, Curaleaf rejected Aurora’s assertions of inaccuracies in its unsolicited bid and accused the Canadian firm of using selective metrics to deflect from years of underperformance.…
ACB — Frequently Asked Questions
What is the current share price of Aurora Cannabis Inc. (ACB)?
As of 2026-09-19 21:16 PDT, Aurora Cannabis Inc. (ACB) trades at $3.87 on NasdaqCM. Its 52-week range is $2.58 to $6.23.
What is the market capitalisation of ACB?
Aurora Cannabis Inc. (ACB) has a market capitalisation of $245.01M on NasdaqCM.
What is the P/E ratio of ACB?
ACB trades at a trailing price-to-earnings (P/E) ratio of -5.86. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.65.
What is the return on equity (ROE) of ACB?
ACB has a return on equity (ROE) of -9.40%. Its return on capital employed (ROCE) is -8.74%.
Is ACB a good stock to buy?
This page provides a data-driven analysis of Aurora Cannabis Inc. (ACB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.